Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lepu Medical Technology (Beijing) Co., Ltd. (300003.SZ)
Beijing, CN
Established in 1999 and headquartered in Beijing, China, Lepu Medical Technology is a prominent company dedicated to the research, development, production, and sale of a broad spectrum of medical devices, pharmaceuticals, and healthcare services. The company's extensive medical device portfolio primarily focuses on cardiovascular health. This includes interventional cardiology products such as coronary stents, balloons, catheters, guide wires, and related PCI accessories. It also provides solutions for structural heart diseases, like occluders, vascular plugs, delivery systems, and mechanical heart valves. Lepu Medical offers cardiac rhythm management products, including pacemakers, equipment, leads, and electrophysiology systems, alongside products for off-pump coronary artery bypass grafting and peripheral interventional devices such as PTA balloons and guide wires. Beyond cardiovascular applications, their offerings extend to critical care products like vascular access devices, needle-free connectors, blood samplers, and pressure transducers. The company also provides digital subtraction angiography (DSA) systems (both floor and suspended types), in vitro diagnostic (IVD) equipment and biomarkers, hemodialysis catheters and hollow fiber dialyzers, and general surgery instruments including surgical staplers and endo surgery accessories. In the pharmaceutical sector, Lepu Medical manufactures and distributes medications for various conditions. This encompasses a comprehensive range of cardiovascular drugs designed to treat issues like thrombosis, hyperlipidemia, hypertension, angina, and heart failure. Additionally, they produce beta-lactamase antibiotics and antifungal antimicrobial drugs, central nervous system medications (such as painkillers and antidepressants), treatments for gastric/duodenal ulcers and chronic liver disease, respiratory system drugs, hypoproteinemia drugs, and agents that activate blood circulation. Furthermore, Lepu Medical provides a diverse array of healthcare services. These include precision medicine, remote ECG telemonitoring, and specialized consulting and management centers for cardiovascular diseases. The company is also involved in medical science and technology incubation, equity investment, and offers medical financial services. Its service offerings extend to general health consultation, online pharmacy platforms, sales of household medical equipment, smart medical devices, and the operation of specialized hospitals focusing on cardiovascular care. Lepu Medical actively participates in the establishment and co-construction of cardiac catheterization laboratories (Cath Labs).
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.45% | -2.93% | -12.13% | -31.36% | -20.89% | -20.24% | +9.65% | -49.38% | -62.11% | -27.15% | -20.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | +1 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+6.2% Q1'26: -3.7% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+300.0% ★ Q1'26: -38.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+7.1% Q1'26: +3.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+21.5% ★ Q1'26: +22.8% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+5.9% ★ Q1'26: +6.7% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.3% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.21× Q1'26: 3.76× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 7 Rev. Ana. 8 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.77B
est: 2.84B (-2.6%)
|
3.47B
est: 3.48B (-0.2%)
|
4.54B
est: 4.53B (+0.2%)
|
6.36B
est: 6.19B (+2.8%)
|
7.80B
est: 8.05B (-3.2%)
|
8.04B
est: 8.24B (-2.5%)
|
10.66B
est: 10.66B (0.0%)
|
10.61B
est: 9.87B (+7.5%)
|
7.98B
est: 7.06B (+13.0%)
|
6.10B
est: 6.19B (-1.4%)
|
6.48B
est: 6.61B (-1.9%)
|
7.05B
6.90B – 7.34B
+6.6% YoY
|
8.02B
7.34B – 8.83B
+13.8% YoY
|
8.89B
8.82B – 8.97B
+10.8% YoY
|
| EBITDA |
836.84M
est: 738.17M (+13.4%)
|
1.09B
est: 902.37M (+21.0%)
|
1.49B
est: 1.18B (+26.8%)
|
1.94B
est: 1.61B (+20.6%)
|
2.48B
est: 2.09B (+18.7%)
|
2.46B
est: 2.14B (+15.1%)
|
3.00B
est: 2.77B (+8.6%)
|
3.20B
est: 2.56B (+25.1%)
|
2.04B
est: 1.84B (+10.7%)
|
927.05M
est: 1.61B (-42.6%)
|
2.03B
est: 1.73B (+17.8%)
|
1.84B
1.80B – 1.92B
+6.6% YoY
|
2.09B
1.91B – 2.30B
+13.8% YoY
|
2.32B
2.30B – 2.34B
+10.8% YoY
|
| EBIT |
705.22M
est: 589.45M (+19.6%)
|
924.90M
est: 720.57M (+28.4%)
|
1.28B
est: 939.22M (+36.8%)
|
1.70B
est: 1.28B (+32.9%)
|
2.20B
est: 1.67B (+31.6%)
|
2.08B
est: 1.71B (+21.5%)
|
2.61B
est: 2.21B (+18.2%)
|
2.79B
est: 2.05B (+36.6%)
|
1.59B
est: 1.40B (+13.6%)
|
427.99M
est: 1.23B (-65.2%)
|
1.39B
est: 1.31B (+6.1%)
|
1.40B
1.37B – 1.46B
+6.6% YoY
|
1.59B
1.46B – 1.75B
+13.8% YoY
|
1.77B
1.75B – 1.78B
+10.8% YoY
|
| Net Income |
520.89M
est: 616.11M (-15.5%)
|
679.26M
est: 711.61M (-4.5%)
|
899.09M
est: 928.40M (-3.2%)
|
1.22B
est: 1.34B (-9.1%)
|
1.73B
est: 1.81B (-4.6%)
|
1.80B
est: 2.19B (-17.6%)
|
1.72B
est: 1.76B (-2.1%)
|
2.20B
est: 2.20B (+0.4%)
|
1.26B
est: 993.96M (+26.6%)
|
246.94M
est: 354.28M (-30.3%)
|
962.01M
est: 1.02B (-5.7%)
|
1.12B
972.88M – 1.15B
+9.7% YoY
|
1.41B
1.19B – 1.48B
+25.5% YoY
|
1.59B
1.41B – 1.75B
+13.1% YoY
|
| SGA |
753.40M
est: 843.09M (-10.6%)
|
1.09B
est: 1.03B (+5.8%)
|
1.42B
est: 1.34B (+5.6%)
|
2.37B
est: 1.83B (+29.3%)
|
2.72B
est: 2.39B (+14.0%)
|
2.40B
est: 2.44B (-1.9%)
|
2.83B
est: 3.16B (-10.6%)
|
2.75B
est: 2.93B (-6.0%)
|
2.40B
est: 1.84B (+30.2%)
|
2.19B
est: 1.62B (+35.6%)
|
787.65M
est: 1.73B (-54.4%)
|
1.84B
1.80B – 1.92B
+6.6% YoY
|
2.09B
1.92B – 2.31B
+13.8% YoY
|
2.32B
2.30B – 2.34B
+10.8% YoY
|
| EPS |
0.32
est: 0.33 (-4.0%)
|
0.39
est: 0.39 (+1.3%)
|
0.50
est: 0.50 (-0.5%)
|
0.69
est: 0.73 (-4.9%)
|
0.97
est: 0.98 (-0.9%)
|
1.01
est: 1.18 (-14.6%)
|
0.96
est: 0.95 (+1.1%)
|
1.22
est: 1.19 (+2.7%)
|
0.68
est: 0.54 (+27.0%)
|
0.13
est: 0.19 (-31.6%)
|
0.52
est: 0.55 (-5.0%)
|
0.59
0.53 – 0.62
+7.9% YoY
|
0.71
0.65 – 0.80
+20.9% YoY
|
0.82
0.76 – 0.95
+14.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck ChiNext ETF CNXT | 0.22% | 263.9K | 0.65% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.15% | 56.2K | 0.65% |
| 3 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.05% | 8.4K | 0.65% |
| 4 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.04% | 28.7K | 0.55% |
| 5 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.02% | 442.9K | 0.58% |
| 6 | Franklin FTSE China ETF FLCH | 0.01% | 35.9K | 0.19% |
| 7 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 151.8K | 0.19% |
| 8 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 4.1K | 0.15% |
| 9 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 134.3K | 0.46% |
| 10 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 27.0K | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bing Feng Zhang | Deputy General Manager | — | male |
| Fei Pu | Chief Executive Officer & Non Independent Director | — | female |
| Weina Jiang | Secretary of the Board | — | female |
| Xiaoying Feng | Deputy General Manager | — | female |
| Yong Wang | Senior VP & CFO | — | female |
| Zhan Jiang Wei | Senior Deputy General Manager | — | male |
| Zhongjie Pu | Chairman & Chief Technology Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300003.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
